UF Health Records Link Glucosamine to 25% Higher MCI-to-Dementia Progression
Observational UF data associate glucosamine with faster MCI progression via glycosylation pathways, but lack causal proof. The findings highlight metabolic contributions to neurodegeneration and the need for targeted trials before changing supplement guidance.
Researchers mined deidentified UF Health electronic records spanning 2012-2024 using AI to identify 1,896 ADRD and 2,750 MCI cases, of which 8% reported glucosamine use. After demographic adjustment, the supplement correlated with accelerated progression and higher death risk in the dementia cohort. Parallel experiments in human brain tissue and mouse models pointed to hyperactive protein glycosylation as a plausible mechanism amplifying neurodegeneration once cognitive impairment is present.
The observational design cannot establish causation; unmeasured lifestyle or comorbidity differences between supplement users and non-users remain possible confounders. This fits broader evidence that metabolic dysregulation, including altered glycosylation and glucose handling, contributes to Alzheimer's beyond amyloid plaques, echoing findings from earlier cohort studies on diabetes and brain aging.
A randomized trial stopping or continuing glucosamine in MCI patients would be required to test causality and guide clinical advice. Until then, the data add a metabolic lens to supplement safety questions for older adults already showing cognitive decline.
The study was published in Nature Metabolism.
Ramon Sun: A 500-patient RCT of glucosamine withdrawal in MCI will report no progression difference at 24 months if the association is non-causal.
Sources (2)
- [1]Primary Source(https://www.nature.com/articles/s42255-026-01345-6)
- [2]Supporting Source(https://jamanetwork.com/journals/jamaneurology/fullarticle/2801234)